Rezafungin
Also known as: CD101, Rezafungin, rezafungin acetate, Rezzayo
Source Rezafungin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Rezafungin (CD101) is a semisynthetic, long‑acting echinocandin administered intravenously once weekly for the treatment of candidemia and invasive candidiasis in adults.
Mechanism of Action
Inhibits fungal β‑1,3‑D‑glucan synthase, leading to impaired cell‑wall synthesis and fungal cell death
Routes of Administration
Goals & Uses
- Activity against echinocandin-resistant CandidaResistant Organism CoverageLow
- Invasive candidiasis treatmentAntifungalHigh
- Treatment of invasive candidiasisAntifungalHigh
- Candidemia treatmentInfectious DiseaseHigh
- Prophylaxis in neutropenic patientsPreventionModerate
- Treatment of candidemiaAntifungal TherapyHigh
- Antifungal prophylaxis in hematopoietic stem cell transplant recipientsProphylaxisModerate
Contraindications
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to rezafungin or other echinocandinsAllergyHigh
Adverse Effects
- HypokalemiaElectrolyteCommon
- AnemiaHematologicCommonLow red blood cell count or hemoglobin
- Elevated liver enzymes (ALT/AST)HepaticUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Elevated liver enzymes (ALT, AST)HepaticUncommon
- Infusion‑related reactions (e.g., flushing, rash)GeneralCommon
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- CyclosporineLow
- Strong CYP3A4 inducers (e.g., rifampin)Moderate
- TacrolimusLow
- Azoles (e.g., fluconazole)Low
Population Constraints
- Pediatric patients (<18 years)AgeAbsolute
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalEMA review ongoing; clinical trials completed.
- United StatesApprovedApproved: candidemia, invasive candidiasisFDA approval 2023; once‑weekly IV dosing.
- United KingdomUnknownPost-Brexit regulatory status not confirmed at time of knowledge cutoff
Approved by the FDA (2023) for invasive candidiasis and candidemia; under review in the EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Rezafungin?
Rezafungin (CD101) is a semisynthetic, long‑acting echinocandin administered intravenously once weekly for the treatment of candidemia and invasive candidiasis in adults.
What is Rezafungin used for?
Rezafungin is educationally associated with: Activity against echinocandin-resistant Candida, Invasive candidiasis treatment, Treatment of invasive candidiasis, Candidemia treatment, Prophylaxis in neutropenic patients, Treatment of candidemia, Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Educational only — not medical advice.
How is Rezafungin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Rezafungin?
Reported adverse effects include: Hypokalemia, Anemia, Elevated liver enzymes (ALT/AST), Nausea, Vomiting, Elevated liver enzymes (ALT, AST), Infusion‑related reactions (e.g., flushing, rash), Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Rezafungin?
Recorded contraindications: Severe hepatic impairment (Child‑Pugh C), Pregnancy, Known hypersensitivity to rezafungin or other echinocandins. Consult a qualified clinician before use.